운전자본 팽창 → 현금 고갈 → 유동성 위기
Warning순운전자본이 +24.6% 팽창하며 현금이 묶이고 있다. 영업CF/순이익 비율이 -58%로 이익 대비 현금 회수가 부족하고, 유동비율도 12.27에서 11.90로 하락했다.
Evidence
순운전자본 YoY +24.6%영업CF/순이익 -58%유동비율 12.27→11.90
Agios Pharmaceuticals
AGIO-US · Nasdaq$30.02-8.34%
2026-07-31 closeAgios Pharmaceuticals — pricey right now, or cheap? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
759 picks
Next-day win rate
58.8%
Avg next-day
+0.55%
vs market
+0.45%p
Beat the market on 57.6% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-30 27.3%07-29 30.8%07-28 11.1%07-27 50%07-24 28.6%07-23 44.4%07-22 50%07-21 60%07-20 33.3%07-17 37.5%07-16 16.7%07-15 50%
This stock flashed this signal 1 time over the last ~2 years (see the signal history below for each date).
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 759 건강관리 peers · not investment advice
Valuation in its own history
PER 2.6 · PBR 1.14 — own history (2013-07~) percentiles 90/100 · 90/100
PER90/100
PBR90/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 19.11
Distress
Grey
Safe
- Altman Z''
- 19.11
- Beneish M-Score
- 2.32
- Sloan accrual
- 63.95%
Statistical manipulation-risk signal
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
4/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score4/9
Profitability
- Positive ROAPass
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtPass
- Higher current ratioNot passed
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -1068%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
USAs of 2026-08-03건강관리
This stock is in 건강관리: revenue rank 353 of 553, share 0%.
353 / 5530%revenue share
Who dominates this industry?
- 1CVS Health14.1%
- 2McKesson13.6%
- 3Cigna9.4%
- 4Cardinal Health8.4%
- 5Centene6.2%
- 6Agios Pharmaceuticals0%
Concentration
DistributedCR3 37.1%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 159.97
- Direction
- 축소
- Level
- 넓음
- Years
- 22
Value lens
- P90/P10
- 23.8
- Median P/B
- 3.07
- Level
- 넓음
- n
- 467
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 1,817.6%
- Interest coverage
- 64.2x
- Return on equity (ROE)
- 43.7%
Operating margin −5pp
TolerableInterest coverageBase 64.2x adverse case 64.1x
Return on equity (ROE)Base 43.7% adverse case 42.3%
Revenue −15%
TolerableInterest coverageBase 64.2x adverse case 54.6x
Return on equity (ROE)Base 43.7% adverse case 35.9%
Interest rate +2pp
TolerableInterest coverageBase 64.2x adverse case 51.9x
Return on equity (ROE)Base 43.7% adverse case 42.2%
Interest coverage limit
Current margin 1,789.3ppInterest coverage limit at an operating margin of 28.3%
Interest expense coverage threshold
Financials at a glance
Agios Pharmaceuticals's latest results and balance sheet. The bars track the last three periods.
Connections
AI-extracted related companies · for reference
Suppliers
국립보건원(NIH)
Customers
Servier
Competitors
📦 ETFs holding this stock
by weight · top-10 constituents basisPassive money holding this stock ≈ $1M(lower bound — top-10 basis, not a forecast)
Factual holdings info from daily disclosures — not a recommendation.
Look up another stock →Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
Signal history (last ~2 years)
Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.
Strong buy (52w high + volume)×1
26-07-07·
Golden cross×1
26-07-14·
New MA alignment×4
26-07-20·26-07-07·26-07-02-20.1%26-06-23+1.3%
“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy